Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 09:15 ET | Source: Marker Therapeutics

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data MT-601 demonstrated robust safety profile with no dose...
October 31, 2025 16:30 ET | Source: Cellectis Inc.

Cellectis to Report Third Quarter Financial Results on November 7, 2025

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
October 29, 2025 12:35 ET | Source: Tevogen Bio Inc

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to...
October 16, 2025 15:19 ET | Source: Cellectis Inc.

Le R&D Day de Cellectis souligne le potentiel de lasmé-cel pour combler un besoin médical majeur non satisfait chez les patients atteints de LAL-B en rechute ou réfractaire

○ Efficacité : taux de réponse global (ORR) de 68 % avec le Process 2 de lasmé-cel (P2) (n=22) ; 83 % à la dose recommandée de Phase 2 (RP2D, n=12) ; et 100 % dans la population cible de Phase 2...
October 16, 2025 15:19 ET | Source: Cellectis Inc.

Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL

○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated...
October 16, 2025 07:00 ET | Source: Cellectis Inc.

Cellectis organise aujourd’hui son R&D Day pour présenter les avancées de son portefeuille et ses perspectives à long terme

L’ensemble des données de phase 1 et la stratégie de l’essai clinique pivot de phase 2 pour le produit candidat lasmé-cel (UCART22) dans la LAL-B en rechute ou réfractaire, seront présentées durant...
October 16, 2025 07:00 ET | Source: Cellectis Inc.

Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers

Event features full Phase 1 data and pivotal Phase 2 strategy for lasme-cel (UCART22) in r/r B-ALL NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS -...
October 14, 2025 08:00 ET | Source: Tr1X, Inc.

Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing

Tr1X announced the FDA has cleared its IND application for TRX319 in progressive multiple sclerosis and a $50M financing that extends its runway into 2027.
October 14, 2025 08:00 ET | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets

SINGAPORE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing...
October 02, 2025 07:00 ET | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia

SINGAPORE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing...